Shelter Pharma is currently trading at Rs. 30.60, up by 0.22 points or 0.72% from its previous closing of Rs. 30.38 on the BSE.
The scrip opened at Rs. 30.00 and has touched a high and low of Rs. 30.60 and Rs. 30.00 respectively. So far 6000 shares were traded on the counter.
The BSE group 'M' stock of face value Rs. 10 has touched a 52 week high of Rs. 50.00 on 25-Aug-2025 and a 52 week low of Rs. 26.50 on 30-Mar-2026.
Last one week high and low of the scrip stood at Rs. 31.20 and Rs. 29.00 respectively. The current market cap of the company is Rs. 51.18 crore.
The promoters holding in the company stood at 44.99%, while non-institutions held 55.01% stake in the company.
Shelter Pharma has received repeat international purchase orders from an existing overseas customer, Taha Drugs & Chemicals Co in the normal course of business. The company has received purchase orders for supply of nutraceutical products.
These repeat orders reflect continued trust and satisfaction of the customer in the company’s products and services and signify strengthening business relations in the international market. The development is expected to further enhance the company’s global presence and contribute positively to its revenue and overall business growth. Broad commercial consideration or size of the orders is $84,450. The orders are to be executed within the mutually agreed timelines as per purchase order and shipment schedule.
Shelter Pharma is engaged in the business of manufacturing herbal products with well-built presence in Human Pharma as well as Veterinary.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1820.75 |
| Dr. Reddys Lab | 1270.95 |
| Cipla | 1333.55 |
| Zydus Lifesciences | 911.85 |
| Lupin | 2343.40 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: